A new preclinical study in Science Translational Medicine shows that folate receptor alpha (FOLR1) helps colorectal tumors resist immune checkpoint blockade by disrupting STAT1 signaling and downshifting MHC-1 activity, limiting CD8+ T-cell recognition. Researchers led by Siqi Chen and colleagues linked higher FOLR1 expression in patient samples to worse outcomes, then confirmed the resistance pathway in tumor and immune co-culture experiments. The team used the clinically approved antibody-drug conjugate mirvetuximab soravtansine, targeting FOLR1. In mouse models, inhibiting FOLR1 restored anti-tumor immunity and resensitized tumors to anti-PD-1 blockade, reversing the immune evasion phenotype. The work reframes a major barrier in colorectal cancer immunotherapy—limited single-agent efficacy—around a specific actionable target within the tumor’s immune interaction biology.